Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02400476 | An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide | completed | Phase 2 | 563 | Puma Biotechnology, Inc.INDUSTRY | 7 | May 6, 2022 | clinicaltrials |
| NCT02698891 | Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer | completed | Phase 2 | 127 | Dana-Farber Cancer InstituteOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT02513472 | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)(ENHANCE-1) | completed | Phase 1 / Phase 2 | 258 | Eisai Inc.INDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT01033032 | Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 78 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT00248703 | Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow | completed | Phase 2 | 1,128 | Oslo University HospitalOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT01293682 | Effects of High Dose Calcitriol in Breast Cancer Patients | completed | Phase 2 | 12 | University of RochesterOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03254654 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03628066 | Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer | completed | Phase 2 | 24 | NSABP Foundation IncNETWORK | 2 | Apr 20, 2022 | clinicaltrials |
| NCT02771353 | The HeartSpare Plus 1B Trial | completed | Phase 2 | 39 | Royal Marsden NHS Foundation TrustOTHER | 0 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT01670877 | Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | completed | Phase 2 | 56 | Washington University School of MedicineOTHER | 2 | Apr 15, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03045653 | Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer | completed | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT01204242 | IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: | completed | Phase 2 | 78 | University of VirginiaOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT02384239 | A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | completed | Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02659514 | Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer | completed | Phase 2 | 67 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02729701 | Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation | completed | Phase 2 | 28 | University of Kansas Medical CenterOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01831076 | Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors | completed | Phase 2 | 36 | University of Colorado, DenverOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT00566618 | Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis | completed | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT02387099 | Dose EScalation Induction of EvERolimus(Desiree) | completed | Phase 2 | 156 | GBG Forschungs GmbHOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02000882 | STAR Cape+BKM120 MBC With Brain Met | completed | Phase 2 | 10 | US Oncology ResearchINDUSTRY | 1 | Feb 7, 2022 | clinicaltrials |
| NCT03243838 | Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer(LANCET) | completed | Phase 2 | 31 | Guangdong Provincial People's HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02297412 | Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel | completed | Phase 2 | 47 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT02418689 | Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens | completed | Phase 2 | 106 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Jan 20, 2022 | clinicaltrials |
| NCT02296801 | A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer(PALLET) | completed | Phase 2 | 307 | NSABP Foundation IncNETWORK | 3 | Jan 13, 2022 | clinicaltrials |
| NCT01988571 | Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) | completed | Phase 2 | 279 | Wake Forest University Health SciencesOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT03608865 | Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing | completed | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT01849250 | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2021 | clinicaltrials |
| NCT03316586 | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT00952692 | Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 12 | Michael Morse, MDOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02595372 | Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy | completed | Phase 2 | 42 | Kathy MillerOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04143282 | Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment | completed | Phase 2 | 250 | Hager salah el dinOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT00629499 | Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer | completed | Phase 2 | 63 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT00193206 | Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | completed | Phase 2 | 123 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT00866905 | Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer | completed | Phase 2 | 168 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT00405938 | Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer | completed | Phase 2 | 79 | SCRI Development Innovations, LLCOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT01421017 | Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | completed | Phase 1 / Phase 2 | 31 | NYU Langone HealthOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT00297596 | Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer | completed | Phase 2 | 25 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT00193050 | Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer | completed | Phase 2 | 110 | SCRI Development Innovations, LLCOTHER | 0 | Oct 26, 2021 | clinicaltrials |
| NCT00444535 | Lapatinib and Bevacizumab for Metastatic Breast Cancer | completed | Phase 2 | 52 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 25, 2021 | clinicaltrials |
| NCT01008150 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | completed | Phase 2 | 141 | NSABP Foundation IncNETWORK | 5 | Oct 25, 2021 | clinicaltrials |
| NCT01466270 | Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction | completed | Phase 2 | 62 | Wake Forest University Health SciencesOTHER | 0 | Oct 20, 2021 | clinicaltrials |
| NCT03890744 | ModraDoc006/r in Patients With Breast Cancer | completed | Phase 2 | 12 | Modra PharmaceuticalsINDUSTRY | 3 | Oct 19, 2021 | clinicaltrials |
| NCT02018458 | Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer | completed | Phase 1 / Phase 2 | 10 | Baylor Research InstituteOTHER | 1 | Oct 11, 2021 | clinicaltrials |
| NCT03078751 | Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer(EarLEE-1) | completed | Phase 2 | 54 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT02366130 | Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer | completed | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 7, 2021 | clinicaltrials |
Data updated 24 days agoSource updated May 6, 2022source: clinicaltrials